Medical therapy to prevent recurrence of ventricular arrhythmia in normal and structural heart disease patients

References

• Curtis MJ, Hancox JC, Farkas A, et al. The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol Ther. 2013;139(2):213–248.
   PubMed Web of Science ®Google Scholar
• Jackson E, Bellenger N, Seddon M, et al. Ischaemic and non-ischaemic cardiomyopathies–cardiac MRI appearances with delayed enhancement. Clin Radiol. 2007;62(5):395–403.
   PubMed Web of Science ®Google Scholar
• Klopotowski M, Kukula K, Malek LA, et al. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. J Cardiol. 2016;68(1):49–56.
   PubMed Web of Science ®Google Scholar
• Nadel J, Lancefield T, Voskoboinik A, et al. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging. 2015;16(6):634–641.
   PubMed Web of Science ®Google Scholar
• Kim EK, Chattranukulchai P, Klem I. Cardiac magnetic resonance scar imaging for sudden cardiac death risk stratification in patients with non-ischemic cardiomyopathy. Korean J Radiol. 2015;16(4):683–695.
   PubMed Web of Science ®Google Scholar
• Rubenstein JC, Lee D, Wu E, et al. A comparison of cardiac magnetic resonance imaging peri-infarct border zone quantification strategies for the prediction of ventricular tachyarrhythmia inducibility. Cardiol J. 2013;20(1):68–77.
   PubMed Web of Science ®Google Scholar
• Viskin S, Rosso R, Rogowski O, et al. The “short-coupled” variant of right ventricular outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia? J Cardiovasc Electrophysiol. 2005;16(8):912–916.
   PubMed Web of Science ®Google Scholar
• Gerstein WH, Gerstein NS, Sandoval A, et al. Malignant conversion of benign right ventricular outflow track ventricular tachycardia 18 years post-ablation. J Arrhythm. 2015;31(4):240–242.
   PubMedGoogle Scholar
• Kim YR, Nam GB, Kwon CH, et al. Second coupling interval of nonsustained ventricular tachycardia to distinguish malignant from benign outflow tract ventricular tachycardias. Heart Rhythm. 2014;11(12):2222–2230.
   PubMed Web of Science ®Google Scholar
• Kurosaki K, Nogami A, Shirai Y, et al. Positive QRS complex in lead i as a malignant sign in right ventricular outflow tract tachycardia: comparison between polymorphic and monomorphic ventricular tachycardia. Circ J. 2013;77(4):968–974.
   PubMed Web of Science ®Google Scholar
• Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol. 2005;46(7):1288–1294.
   PubMed Web of Science ®Google Scholar
• Shimizu W. Arrhythmias originating from the right ventricular outflow tract: how to distinguish “malignant” from “benign”? Heart Rhythm. 2009;6(10):1507–1511.
   PubMed Web of Science ®Google Scholar
• The AVID Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The antiarrhythmics versus implantable defibrillators (AVID) investigators. N Engl J Med. 1997;337(22):1576–1583.
   PubMed Web of Science ®Google Scholar
• The ESVEM Investigators. The ESVEM trial. Electrophysiologic study versus electrocardiographic monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. The ESVEM investigators. Circulation. 1989;79(6):1354–1360.
   PubMed Web of Science ®Google Scholar
• Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol. 2011;22(6):663–668.
   PubMed Web of Science ®Google Scholar
• Hamon D, Blaye-Felice MS, Bradfield JS, et al. A new combined parameter to predict premature ventricular complexes induced cardiomyopathy: impact and recognition of epicardial origin. J Cardiovasc Electrophysiol. 2016;27(6):709–717.
   PubMed Web of Science ®Google Scholar
• Sadron Blaye-Felice M, Hamon D, Sacher F, et al. Premature ventricular contraction-induced cardiomyopathy: related clinical and electrophysiologic parameters. Heart Rhythm. 2016;13(1):103–110.
   PubMed Web of Science ®Google Scholar
• Tan AY, Hu YL, Potfay J, et al. Impact of ventricular ectopic burden in a premature ventricular contraction-induced cardiomyopathy animal model. Heart Rhythm. 2016;13(3):755–761.
   PubMed Web of Science ®Google Scholar
• Potfay J, Kaszala K, Tan AY, et al. Abnormal left ventricular mechanics of ventricular ectopic beats: insights into origin and coupling interval in premature ventricular contraction-induced cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8(5):1194–1200.
   PubMed Web of Science ®Google Scholar
• Yarlagadda RK, Iwai S, Stein KM, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation. 2005;112(8):1092–1097.
   PubMed Web of Science ®Google Scholar
• Zhong L, Lee YH, Huang XM, et al. Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: a single-center retrospective study. Heart Rhythm. 2014;11(2):187–193.
   PubMed Web of Science ®Google Scholar
• Yokokawa M, Good E, Crawford T, et al. Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes. Heart Rhythm. 2013;10(2):172–175.
   PubMed Web of Science ®Google Scholar
• Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7(7):865–869.
   PubMed Web of Science ®Google Scholar
• Hasdemir C, Yuksel A, Camli D, et al. Late gadolinium enhancement CMR in patients with tachycardia-induced cardiomyopathy caused by idiopathic ventricular arrhythmias. Pacing Clin Electrophysiol. 2012;35(4):465–470.
   PubMed Web of Science ®Google Scholar
• Lerman BB, Stein KM, Markowitz SM. Idiopathic right ventricular outflow tract tachycardia: a clinical approach. Pacing Clin Electrophysiol. 1996;19(12 Pt 1):2120–2137.
   PubMed Web of Science ®Google Scholar
• Iwai S, Cantillon DJ, Kim RJ, et al. Right and left ventricular outflow tract tachycardias: evidence for a common electrophysiologic mechanism. J Cardiovasc Electrophysiol. 2006;17(10):1052–1058.
   PubMed Web of Science ®Google Scholar
• Kim RJ, Iwai S, Markowitz SM, et al. Clinical and electrophysiological spectrum of idiopathic ventricular outflow tract arrhythmias. J Am Coll Cardiol. 2007;49(20):2035–2043.
   PubMed Web of Science ®Google Scholar
• Nogami A, Naito S, Tada H, et al. Demonstration of diastolic and presystolic Purkinje potentials as critical potentials in a macroreentry circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J Am Coll Cardiol. 2000;36(3):811–823.
   PubMed Web of Science ®Google Scholar
• Chu J, Sun Y, Zhao Y, et al. Identification of the slow conduction zone in a macroreentry circuit of verapamil-sensitive idiopathic left ventricular tachycardia using electroanatomic mapping. J Cardiovasc Electrophysiol. 2012;23(8):840–845.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Kobayashi Y, Maruyama M, et al. Electrophysiological and anatomical background of the fusion configuration of diastolic and presystolic Purkinje potentials in patients with verapamil-sensitive idiopathic left ventricular tachycardia. J Arrhythm. 2015;31(5):261–267.
   PubMedGoogle Scholar
• de Bakker JM, van Capelle FJ, Janse MJ, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation. 1988;77(3):589–606.
   PubMed Web of Science ®Google Scholar
• Kienzle MG, Miller J, Falcone RA, et al. Intraoperative endocardial mapping during sinus rhythm: relationship to site of origin of ventricular tachycardia. Circulation. 1984;70(6):957–965.
   PubMed Web of Science ®Google Scholar
• Cassidy DM, Vassallo JA, Buxton AE, et al. The value of catheter mapping during sinus rhythm to localize site of origin of ventricular tachycardia. Circulation. 1984;69(6):1103–1110.
   PubMed Web of Science ®Google Scholar
• de Bakker JM, Coronel R, Tasseron S, et al. Ventricular tachycardia in the infarcted, Langendorff-perfused human heart: role of the arrangement of surviving cardiac fibers. J Am Coll Cardiol. 1990;15(7):1594–1607.
   PubMed Web of Science ®Google Scholar
• Peters NS, Green CR, Poole-Wilson PA, et al. Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation. 1993;88(3):864–875.
   PubMed Web of Science ®Google Scholar
• Rosman J, Hanon S, Shapiro M, et al. Triggers of sustained monomorphic ventricular tachycardia differ among patients with varying etiologies of left ventricular dysfunction. Ann Noninvasive Electrocardiol. 2006;11(2):113–117.
   PubMed Web of Science ®Google Scholar
• Soejima K, Stevenson W, Sapp J, et al. Endocardial and epicardial radiofrequency ablation of ventricular tachycardia associated with dilated cardiomyopathy: the importance of low-voltage scars. J Am Coll Cardiol. 2004;43(10):1834–1842.
   PubMed Web of Science ®Google Scholar
• Delacretaz E, Stevenson W, Ellison K, et al. Mapping and radiofrequency catheter ablation of the three types of sustained monomorphic ventricular tachycardia in nonischemic heart disease. J Cardiovasc Electrophysiol. 2000;11(1):11–17.
   PubMed Web of Science ®Google Scholar
• Soejima K, Suzuki M, Maisel WH, et al. Catheter ablation in patients with multiple and unstable ventricular tachycardias after myocardial infarction: short ablation lines guided by reentry circuit isthmuses and sinus rhythm mapping. Circulation. 2001;104(6):664–669.
   PubMed Web of Science ®Google Scholar
• Philips B, Madhavan S, James C, et al. High prevalence of catecholamine-facilitated focal ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2013;6(1):160–166.
   PubMed Web of Science ®Google Scholar
• Pratt CM, Francis MJ, Luck JC, et al. Analysis of ambulatory electrocardiograms in 15 patients during spontaneous ventricular fibrillation with special reference to preceding arrhythmic events. J Am Coll Cardiol. 1983;2(5):789–797.
   PubMed Web of Science ®Google Scholar
• El-Sherif N, Myerburg RJ, Scherlag BJ, et al. Electrocardiographic antecedents of primary ventricular fibrillation. Value of the R-on-T phenomenon in myocardial infarction. Br Heart J. 1976;38(4):415–422.
   PubMedGoogle Scholar
• Chow AW, Segal OR, Davies DW, et al. Mechanism of pacing-induced ventricular fibrillation in the infarcted human heart. Circulation. 2004;110(13):1725–1730.
   PubMed Web of Science ®Google Scholar
• Josephson ME, Spielman SR, Greenspan AM, et al. Mechanism of ventricular fibrillation in man. Observations based on electrode catheter recordings. Am J Cardiol. 1979;44(4):623–631.
   PubMed Web of Science ®Google Scholar
• Stec S, Sikorska A, Zaborska B, et al. Benign symptomatic premature ventricular complexes: short- and long-term efficacy of antiarrhythmic drugs and radiofrequency ablation. Kardiol Pol. 2012;70(4):351–358.
   PubMed Web of Science ®Google Scholar
• Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J. 2002;144(6):e10.
   PubMedGoogle Scholar
• Gill JS, Mehta D, Ward DE, et al. Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality. Br Heart J. 1992;68(4):392–397.
   PubMedGoogle Scholar
• Belhassen B, Rotmensch HH, Laniado S. Response of recurrent sustained ventricular tachycardia to verapamil. Br Heart J. 1981;46(6):679–682.
   PubMedGoogle Scholar
• Belhassen B, Shapira I, Pelleg A, et al. Idiopathic recurrent sustained ventricular tachycardia responsive to verapamil: an ECG-electrophysiologic entity. Am Heart J. 1984;108(4 Pt 1):1034–1037.
   PubMed Web of Science ®Google Scholar
• Okumura K, Yamabe H, Tsuchiya T, et al. Characteristics of slow conduction zone demonstrated during entrainment of idiopathic ventricular tachycardia of left ventricular origin. Am J Cardiol. 1996;77(5):379–383.
   PubMed Web of Science ®Google Scholar
• Collins KK, Schaffer MS, Liberman L, et al. Fascicular and nonfascicular left ventricular tachycardias in the young: an international multicenter study. J Cardiovasc Electrophysiol. 2013;24(6):640–648.
   PubMed Web of Science ®Google Scholar
• Yasui K, Shibata T, Yokoyama U, et al. Idiopathic sustained left ventricular tachycardia in pediatric patients. Pediatr Int. 2001;43(1):42–47.
   PubMed Web of Science ®Google Scholar
• Morgera T, Hrovatin E, Mazzone C, et al. Clinical spectrum of fascicular tachycardia. J Cardiovasc Med (Hagerstown). 2013;14(11):791–798.
   PubMed Web of Science ®Google Scholar
• Ohe T, Aihara N, Kamakura S, et al. Long-term outcome of verapamil-sensitive sustained left ventricular tachycardia in patients without structural heart disease. J Am Coll Cardiol. 1995;25(1):54–58.
   PubMed Web of Science ®Google Scholar
• Fishberger SB, Olen MM, Rollinson NL, et al. Creation of partial fascicular block: an approach to ablation of idiopathic left ventricular tachycardia in the pediatric population. Pacing Clin Electrophysiol. 2015;38(2):209–215.
   PubMed Web of Science ®Google Scholar
• Liu Y, Fang Z, Yang B, et al. Catheter ablation of fascicular ventricular tachycardia: long-term clinical outcomes and mechanisms of recurrence. Circ Arrhythm Electrophysiol. 2015;8(6):1443–1451.
   PubMed Web of Science ®Google Scholar
• Wissner E, Menon SY, Metzner A, et al. Long-term outcome after catheter ablation for left posterior fascicular ventricular tachycardia without development of left posterior fascicular block. J Cardiovasc Electrophysiol. 2012;23(11):1179–1184.
   PubMed Web of Science ®Google Scholar
• Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol. 2014;7(2):237–243.
   PubMed Web of Science ®Google Scholar
• Krittayaphong R, Sriratanasathavorn C, Dhumvibhat C, et al. Radiofrequency catheter ablation of ventricular tachycardia from right ventricular outflow tract. J Med Assoc Thai. 2003;86(Suppl 1):S1–S7.
   Google Scholar
• Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American college of cardiology foundation appropriate use criteria task force, heart rhythm society, American heart association, American society of echocardiography, heart failure society of America, society for cardiovascular angiography and interventions, society of cardiovascular computed tomography, and society for cardiovascular magnetic resonance. J Am Coll Cardiol. 2013;61(12):1318–1368.
   PubMed Web of Science ®Google Scholar
• Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359(10):1009–1017.
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–237.
   PubMed Web of Science ®Google Scholar
• Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med. 1999;341(25):1882–1890.
   PubMed Web of Science ®Google Scholar
• Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med. 1991;324(12):781–788.
   PubMed Web of Science ®Google Scholar
• Hallstrom AP, Cobb LA, Yu BH, et al. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol. 1991;68(10):1025–1031.
   PubMed Web of Science ®Google Scholar
• Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature beats and mortality after myocardial infarction. N Engl J Med. 1977;297(14):750–757.
   PubMed Web of Science ®Google Scholar
• Bigger JT Jr., Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 1984;69(2):250–258.
   PubMed Web of Science ®Google Scholar
• Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol. 1984;54(1):31–36.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Davis HT, DeCamilla J, et al. Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation. 1979;60(5):998–1003.
   PubMed Web of Science ®Google Scholar
• Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac arrest study hamburg (CASH). Circulation. 2000;102(7):748–754.
   PubMed Web of Science ®Google Scholar
• Siebels J, Cappato R, Ruppel R, et al. Preliminary results of the Cardiac arrest study hamburg (CASH). CASH investigators. Am J Cardiol. 1993;72(16):109F–113F.
   PubMed Web of Science ®Google Scholar
• Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel antiarrhythmic study of infarct survival (BASIS). J Am Coll Cardiol. 1990;16(7):1711–1718.
   PubMed Web of Science ®Google Scholar
• Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian amiodarone myocardial infarction arrhythmia trial investigators. Lancet. 1997;349(9053):675–682.
   PubMed Web of Science ®Google Scholar
• Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic study versus electrocardiographic monitoring investigators. N Engl J Med. 1993;329(7):445–451.
   PubMed Web of Science ®Google Scholar
• Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic study versus electrocardiographic monitoring investigators. N Engl J Med. 1993;329(7):452–458.
   PubMed Web of Science ®Google Scholar
• Greene HL for the CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE investigators. Am J Cardiol. 1993;72(3):280–287.
   PubMed Web of Science ®Google Scholar
• The CASCADE Investigators. Cardiac arrest in Seattle: conventional versus amiodarone drug evaluation (the CASCADE study). Am J Cardiol. 1991;67(7):578–584.
   PubMed Web of Science ®Google Scholar
• Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. New England J Med. 1999;340(24):1855–1862.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165–171.
   PubMed Web of Science ®Google Scholar
• Bokhari F, Newman D, Greene M, et al. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian implantable defibrillator study (CIDS). Circulation. 2004;110(2):112–116.
   PubMed Web of Science ®Google Scholar
• Pinter A, Akhtari S, O’Connell T, et al. Efficacy and safety of dofetilide in the treatment of frequent ventricular tachyarrhythmias after amiodarone intolerance or failure. J Am Coll Cardiol. 2011;57(3):380–381.
   PubMed Web of Science ®Google Scholar
• Baquero GA, Banchs JE, Depalma S, et al. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies. J Cardiovasc Electrophysiol. 2012;23(3):296–301.
   PubMed Web of Science ®Google Scholar
• Dorian P, Borggrefe M, Al-Khalidi HR, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation. 2004;110(24):3646–3654.
   PubMed Web of Science ®Google Scholar
• Singer I, Al-Khalidi H, Niazi I, et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol. 2004;43(1):39–43.
   PubMed Web of Science ®Google Scholar
• Mendes L, Podrid PJ, Fuchs T, et al. Role of combination drug therapy with a class IC antiarrhythmic agent and mexiletine for ventricular tachycardia. J Am Coll Cardiol. 1991;17(6):1396–1402.
   PubMed Web of Science ®Google Scholar
• Foster MT, Peters RW, Froman D, et al. Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias. Am J Cardiol. 1996;78(1):47–50.
   PubMed Web of Science ®Google Scholar
• Jung W, Mletzko R, Manz M, et al. Efficacy and safety of combination therapy with amiodarone and type I agents for treatment of inducible ventricular tachycardia. Pacing Clin Electrophysiol. 1993;16(4 Pt 1):778–788.
   PubMed Web of Science ®Google Scholar
• Whitford EG, McGovern B, Schoenfeld MH, et al. Long-term efficacy of mexiletine alone and in combination with class Ia antiarrhythmic drugs for refractory ventricular arrhythmias. Am Heart J. 1988;115(2):360–366.
   PubMed Web of Science ®Google Scholar
• Duff HJ, Roden D, Primm RK, et al. Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine. Circulation. 1983;67(5):1124–1128.
   PubMed Web of Science ®Google Scholar
• Widerhorn J, Sager PT, Rahimtoola SH, et al. The role of combination therapy with mexiletine and procainamide in patients with inducible sustained ventricular tachycardia refractory to intravenous procainamide. Pacing Clin Electrophysiol. 1991;14(3):420–426.
   PubMed Web of Science ®Google Scholar
• Toivonen L, Kadish A, Morady F. A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia. Circulation. 1991;84(1):101–108.
   PubMed Web of Science ®Google Scholar
• Waleffe A, Mary-Rabine L, Legrand V, et al. Combined mexiletine and amiodarone treatment of refractory recurrent ventricular tachycardia. Am Heart J. 1980;100(6 Pt 1):788–793.
   PubMed Web of Science ®Google Scholar
• Huelsing DJ, Spitzer KW, Pollard AE. Spontaneous activity induced in rabbit Purkinje myocytes during coupling to a depolarized model cell. Cardiovasc Res. 2003;59(3):620–627.
   PubMed Web of Science ®Google Scholar
• Spitzer KW, Pollard AE, Yang L, et al. Cell-to-cell electrical interactions during early and late repolarization. J Cardiovasc Electrophysiol. 2006;17(Suppl 1):S8–S14.
   Google Scholar
• Kapa S, Venkatachalam KL, Asirvatham SJ. The autonomic nervous system in cardiac electrophysiology: an elegant interaction and emerging concepts. Cardiol Rev. 2010;18(6):275–284.
   PubMed Web of Science ®Google Scholar
• Exner DV, Reiffel JA, Epstein AE, et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol. 1999;34(2):325–333.
   PubMed Web of Science ®Google Scholar
• Hreybe H, Bedi M, Ezzeddine R, et al. Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of beta-blockers. Am Heart J. 2005;150(5):1064.
   PubMed Web of Science ®Google Scholar
• Seidl K, Hauer B, Schwick NG, et al. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. Am J Cardiol. 1998;82(6):744–748.
   PubMed Web of Science ®Google Scholar
• Finzi AA, Latini R, Barlera S, et al. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: a substudy of the Gruppo Italiano per lo Studio della sopravvivenza nell’insufficienza cardiaca (GISSI-HF) trial. Am Heart J. 2011;161(2):338–343.e331.
   PubMed Web of Science ®Google Scholar
• Madsen T, Christensen JH, Thogersen AM, et al. Intravenous infusion of n-3 polyunsaturated fatty acids and inducibility of ventricular tachycardia in patients with implantable cardioverter defibrillator. Europace. 2010;12(7):941–946.
   PubMed Web of Science ®Google Scholar
• Metcalf RG, Sanders P, James MJ, et al. Effect of dietary n-3 polyunsaturated fatty acids on the inducibility of ventricular tachycardia in patients with ischemic cardiomyopathy. Am J Cardiol. 2008;101(6):758–761.
   PubMed Web of Science ®Google Scholar
• Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the study on omega-3 fatty acids and ventricular arrhythmia (SOFA) randomized trial. JAMA. 2006;295(22):2613–2619.
   PubMed Web of Science ®Google Scholar
• Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005;293(23):2884–2891.
   PubMed Web of Science ®Google Scholar
• Khoueiry G, Abi Rafeh N, Sullivan E, et al. Do omega-3 polyunsaturated fatty acids reduce risk of sudden cardiac death and ventricular arrhythmias? A meta-analysis of randomized trials. Heart Lung. 2013;42(4):251–256.
   PubMed Web of Science ®Google Scholar
• Verrier RL, Pagotto VP, Kanas AF, et al. Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. Heart Rhythm. 2013;10(1):121–127.
   PubMed Web of Science ®Google Scholar
• Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34(12):1600–1606.
   PubMed Web of Science ®Google Scholar
• Vizzardi E, D’Aloia A, Salghetti F, et al. Efficacy of ranolazine in a patient with idiopathic dilated cardiomyopathy and electrical storm. Drug Discov Ther. 2013;7(1):43–45.
   PubMedGoogle Scholar
• Yeung E, Krantz MJ, Schuller JL, et al. Ranolazine for the suppression of ventricular arrhythmia: a case series. Ann Noninvasive Electrocardiol. 2014;19(4):345–350.
   PubMed Web of Science ®Google Scholar
• Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305–1323.
   PubMed Web of Science ®Google Scholar
• Koplan BA, Soejima K, Baughman K, et al. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm. 2006;3(8):924–929.
   PubMed Web of Science ®Google Scholar
• Jefic D, Joel B, Good E, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm. 2009;6(2):189–195.
   PubMed Web of Science ®Google Scholar
• Furushima H, Chinushi M, Sugiura H, et al. Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome. Clin Cardiol. 2004;27(4):217–222.
   PubMed Web of Science ®Google Scholar
• Hiramitsu S, Morimoto S, Uemura A, et al. National survey on status of steroid therapy for cardiac sarcoidosis in Japan. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(3):210–213.
   PubMed Web of Science ®Google Scholar
• Yodogawa K, Seino Y, Ohara T, et al. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16(2):140–147.
   PubMed Web of Science ®Google Scholar
• Stees CS, Khoo MS, Lowery CM, et al. Ventricular tachycardia storm successfully treated with immunosuppression and catheter ablation in a patient with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2011;22(2):210–213.
   PubMed Web of Science ®Google Scholar
• Futamatsu H, Suzuki J, Adachi S, et al. Utility of gallium-67 scintigraphy for evaluation of cardiac sarcoidosis with ventricular tachycardia. Int J Cardiovasc Imaging. 2006;22(3–4):443–448.
   PubMed Web of Science ®Google Scholar
• Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol. 1991;18(4):937–943.
   PubMed Web of Science ®Google Scholar
• Banba K, Kusano KF, Nakamura K, et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm. 2007;4(10):1292–1299.
   PubMed Web of Science ®Google Scholar
• Ermakov S, Scheinman M. Arrhythmogenic right ventricular cardiomyopathy - antiarrhythmic therapy. Arrhythm Electrophysiol Rev. 2015;4(2):86–89.
   PubMedGoogle Scholar
• Satomi K, Kurita T, Suyama K, et al. Catheter ablation of stable and unstable ventricular tachycardias in patients with arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol. 2006;17(5):469–476.
   PubMed Web of Science ®Google Scholar
• Leclercq JF, Coumel P. Characteristics, prognosis and treatment of the ventricular arrhythmias of right ventricular dysplasia. Eur Heart J. 1989;10(Suppl D):61–67.
   PubMed Web of Science ®Google Scholar
• Denis A, Sacher F, Derval N, et al. Diagnostic value of isoproterenol testing in arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2014;7(4):590–597.
   PubMed Web of Science ®Google Scholar
• Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Circulation. 2015;132(5):441–453.
   PubMed Web of Science ®Google Scholar
• Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. 1992;86(1):29–37.
   PubMed Web of Science ®Google Scholar
• Marcus GM, Glidden DV, Polonsky B, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC registry. J Am Coll Cardiol. 2009;54(7):609–615.
   PubMed Web of Science ®Google Scholar
• Di Biase L, Santangeli P, Burkhardt DJ, et al. Endo-epicardial homogenization of the scar versus limited substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2012;60(2):132–141.
   PubMed Web of Science ®Google Scholar
• Jais P, Maury P, Khairy P, et al. Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation. 2012;125(18):2184–2196.
   PubMed Web of Science ®Google Scholar
• Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375(2):111–121.
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Locati EH, Moss AJ, et al. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation. 1991;84(2):503–511.
   PubMed Web of Science ®Google Scholar
• Hayase J, Patel J, Narayan SM, et al. Percutaneous stellate ganglion block suppressing VT and VF in a patient refractory to VT ablation. J Cardiovasc Electrophysiol. 2013;24(8):926–928.
   PubMed Web of Science ®Google Scholar
• Vaseghi M, Gima J, Kanaan C, et al. Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up. Heart Rhythm. 2014;11(3):360–366.
   PubMed Web of Science ®Google Scholar
• Hoffmann BA, Steven D, Willems S, et al. Renal sympathetic denervation as an adjunct to catheter ablation for the treatment of ventricular electrical storm in the setting of acute myocardial infarction. J Cardiovasc Electrophysiol. 2013;24(10):1175–1178.
   PubMed Web of Science ®Google Scholar
• Remo BF, Preminger M, Bradfield J, et al. Safety and efficacy of renal denervation as a novel treatment of ventricular tachycardia storm in patients with cardiomyopathy. Heart Rhythm. 2014;11(4):541–546.
   PubMed Web of Science ®Google Scholar
• Grimaldi R, de Luca A, Kornet L, et al. Can spinal cord stimulation reduce ventricular arrhythmias? Heart Rhythm. 2012;9(11):1884–1887.
   PubMed Web of Science ®Google Scholar